Email this page
Print
Bookmark and share
Bigger
Smaller
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Articles on drugs for dementia & Alzheimer's Disease from NPS RADARArticles on drugs for dementia & Alzheimer's Disease from NPS RADAR
| Title | Content Type | Date | Description |
|---|---|---|---|
| Erratum: Memantine (Ebixa) for dementia in moderately severe Alzheimer’s disease | Professional publication - NPS RADAR - Brief item | 2008-12-01 00:00:00 | Information on the dose titration of memantine contained in Table 1 of the NPS RADAR review of memantine in the August issue was incorrect. The dose for the tablet formulation was correct but the dose for the oral solution was mistakenly halved. |
| Rivastigmine (Exelon) patch PBS listed for Alzheimer’s disease | Professional publication - NPS RADAR - Brief item | 2008-08-01 00:00:00 | Rivastigmine transdermal patches (Exelon) were PBS listed for mild to moderate Alzheimer's disease on 1 July 2008. |
| Memantine (Ebixa) for moderately severe Alzheimer’s disease | Professional publication - NPS RADAR - Review | 2008-08-01 00:00:00 | Memantine has a different mechanism of action to the cholinesterase inhibitors. It provides modest improvements in cognitive, psychological and behavioural functioning, but the clinical importance of these improvements is yet to be established. |
| Cholinesterase inhibitors: change in authority requirements for cognitive testing | Professional publication - NPS RADAR - Brief item | 2007-08-01 00:00:00 | A change in the authority requirements for the cholinesterase inhibitors (donepezil hydrochloride, galantamine hydrochloride and rivastigmine hydrogen tartrate) means that the same cognitive test used in the initial treatment authority application must be used in requests for continued treatment. |
| Risperidone (Risperdal) for behavioural disturbances in dementia | Professional publication - NPS RADAR - Review | 2005-04-01 00:00:00 | Reviews use of risperidone for behavioural symptoms in dementia and discusses underlying factors and non-drug interventions. |
| Galantamine (Reminyl) prolonged-release capsules for dementia in Alzheimer's disease | Professional publication - NPS RADAR - Review | 2004-12-01 00:00:00 | Reviews use of galantamine prolonged-release capsules for dementia in Alzheimer's disease, including comparison with immediate-release preparation and long-term therapeutic effect. |
View all RADAR articles by date, by therapeutic topic, or by active ingredient, or find out more about NPS RADAR.
NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.
Date published: 2009-10-28 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
